CDK4 and breast cancer: Although the CDK4/6i cohort was defined as the patients who were prescribed the therapy for the first time, this cohort may have included those who started the CDK 4 and 6 inhibitor therapy as a later line of therapy because the true first-line therapy for advanced breast cancer treatment could not be reliably identified from the claims records.